Liposome–protein corona in a physiological environment: Challenges and opportunities for targeted delivery of nanomedicines
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 3×
“When PEG of different chain lengths was grafted to the surface of immunoliposomes, as short (750 Da), intermediate (2000 Da), or long PEG (5000 Da), DSPE-PEG2000 was the best compromise for extended blood circulation and target binding in vivo.(16,17) For instance, the plasma levels of doxorubicin obtained with PEG/ D…”
BackgroundBiomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., & Dawson, K. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107583h · Cited by 1,835
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Pozzi, D., Colapicchioni, V., Caracciolo, G., Piovesana, S., Capriotti, A. L., Palchetti, S., De Grossi, S., Riccioli, A., Amenitsch, H., & Laganà, A. (2014) · Nanoscale · doi:10.1039/c3nr05559k · Cited by 581 · cited 1×
“PEGmasks the complement-Igs from macrophage uptake and thus supports a prolonged stay of the particles in blood circulation.(93,106) PEG is the polymer of choice to impair opsonization and prolong exposure to the nanoparticles.”
BackgroundSelf-citationLaurent, S., Burtea, C., Thirifays, C., Häfeli, U. O., & Mahmoudi, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029997 · Cited by 171 · cited 1×
“Finally, it is important to be aware of the fact that a single type of liposome–protein corona complex can have a different effect on various cells.(70,72,134) This concept of ‘cell vision’ is yet another crucial factor to be considered when designing novel therapeutic liposomes.”
Background
Cited by
Protein corona: a new approach for nanomedicine design
Nguyen, V. H., & Lee, B.-J. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s129300 · Cited by 638
Zhang, M., Xiao, B., Wang, H., Han, M. K., Zhang, Z., Viennois, E., Xu, C., & Merlin, D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.159 · Cited by 456
Biological Identity of Nanoparticles In Vivo : Clinical Implications of the Protein Corona
Caracciolo, G., Farokhzad, O. C., & Mahmoudi, M. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.011 · Cited by 426
Self-citationStealth Coating of Nanoparticles in Drug-Delivery Systems
Fam, S. Y., Chee, C. F., Yong, C. Y., Ho, K. L., Mariatulqabtiah, A. R., & Tan, W. S. (2020) · Nanomaterials · doi:10.3390/nano10040787 · Cited by 422
Aghebati‐Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., Yousefi, M., & Aghebati‐Maleki, L. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29126 · Cited by 417
Immunological and Toxicological Considerations for the Design of Liposomes
Inglut, C. T., Sorrin, A. J., Kuruppu, T., Vig, S., Cicalo, J., Ahmad, H., & Huang, H.-C. (2020) · Nanomaterials · doi:10.3390/nano10020190 · Cited by 371
Hadjidemetriou, M., Al-Ahmady, Z., Mazza, M., Collins, R. F., Dawson, K., & Kostarelos, K. (2015) · ACS Nano · doi:10.1021/acsnano.5b03300 · Cited by 358
Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake
Mirshafiee, V., Kim, R., Park, S., Mahmoudi, M., & Kraft, M. L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.019 · Cited by 316
“components that are naturally targeted to the desired cells [23].”
Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines
Wang, H.-X., Zuo, Z.-Q., Du, J.-Z., Wang, Y.-C., Sun, R., Cao, Z.-T., Ye, X.-D., Wang, J.-L., Leong, K. W., & Wang, J. (2016) · Nano Today · doi:10.1016/j.nantod.2016.04.008 · Cited by 285
Nonspecific Binding—Fundamental Concepts and Consequences for Biosensing Applications
Frutiger, A., Tanno, A., Hwu, S., Tiefenauer, R. F., Vörös, J., & Nakatsuka, N. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00044 · Cited by 278
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide
Hajipour, M. J., Raheb, J., Akhavan, O., Arjmand, S., Mashinchian, O., Rahman, M., Abdolahad, M., Serpooshan, V., Laurent, S., & Mahmoudi, M. (2015) · Nanoscale · doi:10.1039/c5nr00520e · Cited by 256
Emerging understanding of the protein corona at the nano-bio interfaces
Mahmoudi, M., Bertrand, N., Zope, H., & Farokhzad, O. C. (2016) · Nano Today · doi:10.1016/j.nantod.2016.10.005 · Cited by 250
Chen, T., He, B., Tao, J., He, Y., Deng, H., Wang, X., & Zheng, Y. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.009 · Cited by 186
Peptide ligand-mediated targeted drug delivery of nanomedicines
Jiang, Z., Guan, J., Qian, J., & Zhan, C. (2019) · Biomaterials Science · doi:10.1039/c8bm01340c · Cited by 172
Bigdeli, A., Palchetti, S., Pozzi, D., Hormozi-Nezhad, M. R., Baldelli Bombelli, F., Caracciolo, G., & Mahmoudi, M. (2016) · ACS Nano · doi:10.1021/acsnano.6b00261 · Cited by 157
Self-citationEnhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption
Guan, J., Shen, Q., Zhang, Z., Jiang, Z., Yang, Y., Lou, M., Qian, J., Lu, W., & Zhan, C. (2018) · Nature Communications · doi:10.1038/s41467-018-05384-1 · Cited by 152
Stealth Effect of Biomolecular Corona on Nanoparticle Uptake by Immune Cells
Caracciolo, G., Palchetti, S., Colapicchioni, V., Digiacomo, L., Pozzi, D., Capriotti, A. L., La Barbera, G., & Laganà, A. (2015) · Langmuir · doi:10.1021/acs.langmuir.5b02158 · Cited by 131
Self-citationDigiacomo, L., Cardarelli, F., Pozzi, D., Palchetti, S., Digman, M. A., Gratton, E., Capriotti, A. L., Mahmoudi, M., & Caracciolo, G. (2017) · Nanoscale · doi:10.1039/c7nr06437c · Cited by 109
Self-citationTriptolide delivery: Nanotechnology-based carrier systems to enhance efficacy and limit toxicity
Ren, Q., Li, M., Deng, Y., Lu, A., & Lu, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105377 · Cited by 64
Peinetti, N., Cuello Rubio, M. M., Sosa, L. D. V., Scalerandi, M. V., Alasino, R. V., Peyret, V., Nicola, J. P., Beltramo, D. M., Quintar, A. A., & Maldonado, C. A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119985 · Cited by 7
Metadata
- Authors
- Caracciolo, G.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 11
- Issue
- 3
- Pages
- 543-557
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2011068269
- Cited by
- 246
- References
- 11
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.